General Newsroom Hero 1920x480 (4:1)
Our Work

Latham Advises ATAI Life Sciences on US$125 Million Series C

November 27, 2020
London and Frankfurt teams act for biotechnology company in financing round.

Latham & Watkins advised ATAI Life Sciences, a global biotech platform, in raising US$125 million in a Series C financing round.

The financing was led by Apeiron Investment Group, Peter Thiel and Catalio Capital Management.

Proceeds from the financing will be used primarily to fund pre-clinical and clinical development of ATAI's existing mental health programs, to expand its drug candidate pipeline and further advance ATAI's platform technologies.

The Latham team was led by London corporate partner Robbie McLaren and Frankfurt corporate partner Markus Krueger, with associates Jon Fox and David Funken.